contact-draft
Product Inquiry This is back side content. Get in Touch Quote or Demo This is back side content. Get in Touch Technical Support This is back side content. Get in Touch Partnering Inquiry This is back side content. Get in Touch Media Requests This is back side content. Get in Touch
ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research
ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, announced today that it will begin the pre-commercial launch of its new cell analysis platform, VisionCyte™. The announcement coincides with the 2025 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, CA from January 27-30, 2025, where VisionCyte was named a finalist for the 2025 New Product Award. The launch of VisionCyte extends ThinkCyte’s product portfolio of life science research platforms beyond VisionSort, the company’s flagship product launched in 2023 and adopted by leading biopharmaceutical companies and academic institutions worldwide. The VisionCyte platform leverages high resolution morphological profiling, high-throughput capabilities, and advanced AI analysis […]
Sponsored Webinar: Cell Therapies for Cancer Treatment
We are proud to co-sponsor the upcoming Webinar “Upgrading Cell Therapies for Cancer Treatment” hosted by The Scientist on: Friday, November 15th, 2024 11:30 AM – 12:30 PM ET Topics to be covered CAR T cell therapy challenges in acute myeloid leukemia (AML), including the complexity of target antigen selection Novel CAR T cell therapy approaches Ex vivo and in vivo CRISPR editing to reprogram T cells Using CRISPR to discover new gene circuits, add synthetic receptors and transcriptional programs, and manufacture next-generation CAR T cells Speakers: Paulina Velasquez, MD Associate Member Department of Bone Marrow Transplantation and Cellular Therapy St. Jude Children’s Research Hospital Justin Eyquem, PhD Assistant Professor […]
Distributors
ITALY Cytosens Via San Raffaele, 1 – 20121 Milano (MI)Via Generale De Bonis, 81 – 80123 Napoli (NA)Italy +39 02 947 51269 WEBSITE EMAIL Sweden, Denmark, Finland, Norway LabLife Nordic Rättarens väg 9SE-182 34 DanderydSweden +46 8 755 39 14 WEBSITE EMAIL Israel Almog Diagnostics 4 Oren St.Hi Park Shoham 60850Israel +972-3-9773390 WEBSITE EMAIL Belgium, Netherlands, Luxembourg Future Lab Innovations Nieuweweg 2796603 BN WijchenThe Netherlands +31 (0) 880245750 WEBSITE EMAIL India, Sri Lanka, Bangladesh Prayoga Life Sciences Inc. No.37, Sudarshan Grand Enclave,Sampigehalli Road, ChokanahalliJakkur Post, Bengaluru – 560 064India +91 7506332122 WEBSITE EMAIL Japan Kiko Tech Co., Ltd. KDX Musashikosugi Building 11F3-1200, Nakahara-ku ShinmarukohigashiKawasaki-shi, Kanagawa 211-0004Japan TEL: +81-44-430-3245FAX: +81-44-433-4390 WEBSITE […]
VisionSort on Display at BioJapan 2024
October 9-11, 2024 in Yokohama, Japan The ThinkCyte team will be at be out in full force at BioJapan, Asia’s premier life science research event. Stop by our booth and check out a VisionSort travel unit. Picture the capabilities of deep morphological profiling, AI-driven cell analysis and sorting, and multi-laser fluorescence at work in your lab! For more information on the event, visit https://jcd-expo.jp/en/
ThinkCyte Showcases VisionSort for Drug Discovery at ELRIG 2024
October 2-3 in London, England Come meet the ThinkCyte team at Booth B24 and learn about how you can perform high-throughput, high-content phenotypic drug screening using flow cytometry! This year’s theme of “Connecting Minds, Transforming Science, Empowering the Community” is about collaboration and working together to tackle the challenges of maintaining health and wellbeing, a concept that we embrace everyday at ThinkCyte. For more information on the event visit https://elrig.org/portfolio/drug-discovery-2024/
New Publication Highlights Ghost Cytometry for Quality Control in Cell Therapy Manufacturing
ThinkCyte today announced the publication of a joint research paper together with Astellas Pharma Inc, in the September 19th issue of Scientific Reports showcasing the potential of its Ghost Cytometry® technology for quality control (QC) in cell therapy product manufacturing. As the clinical use of cellular therapies in oncology and autoimmune conditions explodes, the need for efficient and reliable methods to ensure the quality of cell therapy products has become increasingly important. Current QC processes for cell therapy manufacturing involve complex analytical tests, including fluorescence-based flow cytometry, which requires skilled operators, is prone to variability, and can be costly to perform due to the requirement of using expensive antibodies. The […]
ThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
Tokyo, Japan. / Redwood City, CA ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financing secured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 million. The extension round was led by Japan Green Investment Corp. for Carbon Neutrality (JICN), KIRIN-GB Fund I L.P., and SMBC Venture Capital No. 7 Investment Limited Partnership. The company also secured a loan from Japan Finance Corporation. This latest round brings ThinkCyte’s total funding to $91 million, reinforcing the company’s commitment to expanding the global reach of its flagship product, VisionSort™. Since its launch in June 2023, VisionSort™ […]
ThinkCyte to Attend the 34th Annual Conference of the German Society for Cytometry
September 10-13 in Berlin, Germany Come meet the ThinkCyte team and talk label-free cytometry and AI in life science R&D! The annual meeting is designed to cultivate a highly interactive, interdisciplinary and cooperative spirit to advance collaboration, communicate cutting edge approaches in cytometry and promote excellence in the application of cytometric technologies. For more information on the event visit https://dgfz.org/2024/
ThinkCyte to Showcase VisionSort at GLIIFCA’s 33rd Annual Meeting
September 12-14, 2024 at the Marriott Cincinnati Rivercenter in Covington, KY. The ThinkCyte team will be on hand at the Great Lakes International Imaging and Flow Cytometry Association (GLIIFCA) and the Ohio River Valley Cytometry Association’s (ORVCA) 33rd annual meeting. The event will feature an outstanding group of speakers, including not only established senior researchers, but also young investigators passionate about cytometry. For more information on the event visit https://gliifca.org/
CYTO 2024 Showcase
Missed us in person? View our CTYO talks, presentation and posters here. TALKS AND PRESENTATIONS https://vimeo.com/947158088/0d7fe29480https://vimeo.com/948927273/9c34fa0abchttps://vimeo.com/947182969/6d20220fcc POSTER DOWNLOADS Label-free morphological profiling and isolation of immune cell subsets using VisionSort, a novel, AI-based flow cytometry platform DOWNLOAD Label-free morphometric characterization of T cells for cell and gene therapy research and development DOWNLOAD
ThinkCyte Launches New Website and Showcases VisionSort at Global Events
ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website. The company will have a presence at the American Society for Immunology (AAI) from May 3rd to 7th, the Association for Research in Vision and Ophthalmology (ARVO) from May 5th to 9th, and CYTO 2024 presented by the International Society for Advancement of Cytometry (ISAC) from May 4th to 8th. The events will showcase both internal research and development achievements as well as presentations from VisionSort customers on the application of the platform to advance research and therapeutic development efforts. “A year ago […]
ThinkCyte to Exhibit at ARVO 2024
ThinkCyte will attend the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) from May 5th-9th, 2024 in Seattle, WA. Come learn more about VisionSort, the latest in AI-based morphotypic cell analysis and sorting at our Booth (#1240) or our poster!
ThinkCyte to Exhibit at AAI 2024
ThinkCyte will attend the American Association of Immunology Annual Meeting (AAI 2024) from May 3rd-7th, 2024 in Chicago, IL. Come learn more about VisionSort, the latest in AI-based morphotypic cell analysis and sorting at our Booth (#877) or at one of our posters! Sun, May 5: POSTER: Label-free morphological profiling and isolation of immune cell subsets using VisionSort, a novel, AI-based flow cytometry platform POSTER: Label-free morphometric characterization of T cells for cell and gene therapy research and development.
CYTO 2024
Missed us in person? View our CTYO talks, presentation and posters here. Enter your email address below to get access to all CYTO 2024 content VIDEO VisionSort: A Journey from Concept to Customers Sadao Ota, PhD CSO, ThinkCyte Patricia Rogers Associate Director, Flow Cytometry Facility, Broad Institute VIDEO A flow-based high content intracellular phenotypic screening platform combining artificial intelligence (AI)-based morphometric profiling and DNA barcoding. VIDEO Label-free morphometric characterization, sorting, and therapeutic use of stem cells with VisionSort POSTER DOWNLOADS Label-free morphological profiling and isolation of immune cell subsets using VisionSort, a novel, AI-based flow cytometry platform Label-free morphometric characterization of T cells for cell and gene therapy research and […]
Conferences
Meet the ThinkCyte team and learn more about VisionSort. FEATURED CYTO 2024 Missed us at the show? See all our videos, talks and posters in the CYTO Showcase. VIEW UPCOMING EVENTS Northwest Flow Cytometry Society March 19 Seattle, WA Link flowcytometryUK March 26-28 Newcastle, GB Link MetroFlow April 10 Tarrytown, NJ Link
ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones
ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery. Together with a joint research group including investigators at the University of Tokyo and the University of British Columbia, the team describes the development of an approach to identify new candidate drugs by CRISPR screening using Ghost Cytometry; its artificial intelligence (AI)-driven, label-free, morphology-based cell sorting technology. In the publication, ‘Pooled CRISPR screening of high-content cellular phenotypes using ghost cytometry, the team shows how VisionSort can be used to perform both label-free and fluorescence-based screening for a range of phenotypes relevant to drug discovery. Specifically, the […]
Partner with Us
ThinkCyte’s partnering program is designed to help accelerate research and development of novel therapeutics and artificial intelligence (AI)-based approaches in life science. ThinkCyte offers three distinct partnering platforms. The Disease Profiling Platform, the Biopharma Platform, and the AI Platform, each designed to enhance collaboration with industry partners and advance fundamental new discoveries in healthcare. Disease Profiling Platform Biomarker development for diagnostics applications including LDT, IVD, and CDx products Out-licensing for instrument development, including clinical grade point-of-care devices System integration into CLIA labs for advanced diagnostics services with improved workflows AI Platform Co-development of morphometric database with functional, clinical, and / or meta-omic annotations Co-development and validation of novel drug target […]
Webinar: VisionSort for Life Science
Webinar VisionSort: A New Dimension in Cell Analysis & Sorting Registration for this event is closed, but a recording of the event will be available soon. Sign up if you’d like to be notified when it’s released. Join us and learn about the next frontier in cytometry and the new VisionSort platform, from ThinkCyte. ThinkCyte company overview The basics of Ghost Cytometry, the technology powering VisionSort Applications and value propositions of VisionSort in life science R&D including Cell Therapy R&D, Drug Discovery, and Disease Profiling Resources, publications, and additional references
Privacy Policy
This Privacy Policy explains how ThinkCyte K.K. (together with its affiliates, “ThinkCyte”, “we”, or “us”) may collect, use, disclose, and secure information we obtain from you, your visit to our websites or your use of our services (collectively, “Services”). By accessing our website and providing your information directly or via our Services, you expressly consent to this Privacy Policy. If you are visiting from the European Economic Area or other regions with laws governing data collection and use, you agree to the transfer of your information to Japan or the United States and processing globally. How we collect your information We collect information when you visit our website, sign up […]
Welcome
VisionSort VisionSort combines traditional fluorescence flow cytometry with high-dimensional morphological profiling and AI to enable label-free cell sorting and unbiased single cell profiling. LEARN MORE NEW ON-DEMAND WEBINAR Label-free Use of Stem Cells with VisionSort WATCH Application Areas Cell Therapy R&D Label-free immune cell sorting Select therapeutically relevant cells C and GT manufacturing QC Drug Discovery Faster, cheaper alternative to plate-based phenotypic screening Screen a wider range of phenotypes Compatible with small molecule & CRISPR-based approaches Disease Profiling Disease insight….with AI Novel biomarker discovery, uncover novel cell populations, ID new targets, disease characterization, MRD, patient stratification Morphology Based Cell Sorting Characterizing and sorting cells by morphology at record high-throughput rates […]
VisionSort
ON-DEMAND WEBINAR: Label-free Use of Stem Cells with VisionSort WATCH VisionSort Powered by Ghost Cytometry NEW WEBINAR VisionSort for Life Science R&DWednesday, March 27 DETAILS video FEATURES APPLICATIONS specifications brochure resources See your cells in a whole new light. Bringing together fundamental advances in optics, microfluidics, and artificial intelligence (AI), VisionSort empowers researchers to get more from their cells. VisionSort was designed to deliver all the capabilities you have come to expect from traditional fluorescence-only cytometers and adds the strength of morphological profiling and insights of AI. Go beyond conventional cytometry add a new dimension to your cellular analysis and sorting workflows with VisionSort. https://39878021.fs1.hubspotusercontent-na1.net/hubfs/39878021/VIDEO/VIDEO:%20VisionSort%20Platform%20Overview.mp4 VisionSort Features USER DRIVEN […]
Contact Us
Our Mission
ThinkCyte Mission Deeper insights, better treatments — a single cell at a time ThinkCyte’s mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enables the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology. We strive to push the frontiers of human knowledge and understanding to shape the future of biology and medicine. Our values, philosophy, and drive are based upon the desire to accelerate the launch of innovative therapies and diagnostics to improve lives…one cell at a time. OUR VALUES Cultivate your curiosity, expand your expertise ThinkCyte empowers its team members to broaden their […]
Resources
View Publications SORT BY TYPE App Note Brochure Poster Video Webinar White Paper 日本語 All SORT BY APPLICATION Cell Therapy Disease Profiling Drug Discovery All FEATURED DOWNLOAD Artificial Intelligence This Cell Press Selection explores the potential of AI for improving therapeutic development and patient outcomes. DOWNLOAD PUBLICATIONS
Our Team
LEADERSHIP board of directors / co-founders
News
Events News All
Ghost Cytometry
THINKCYTE SCIENCE Label-free, high throughput cell characterization and isolation based on high-resolution morphology and artificial intelligence. Ghost Cytometry, the Science-published technology inside VisionSort, brings artificial intelligence to cytometry to enable high-throughput, data rich, and novel insights for life science R&D. In-depth video https://39878021.fs1.hubspotusercontent-na1.net/hubfs/39878021/VIDEO/TCY-QUICK-VID-FINAL-2024.mp4 NEW ON-DEMAND WEBINAR Label-free Use of Stem Cells with VisionSort WATCH How Ghost Cytometry Works A. Profile Acquisition Cells pass through a structured illumination and morphological profiles are collected as high-dimensional temporal waveforms with a single pixel detector. B. AI-based Classification A trained AI model predicts the cell class based on the waveform. C. Sorting The classified cells are gently isolated using fluid pressure.https://39878021.fs1.hubspotusercontent-na1.net/hubfs/39878021/VIDEO/VIDEO:%20VisionSort%20Platform%20Overview.mp4#t=25 AI-Driven Cell Classification […]
Disease Profiling
High-resolution single cell profiling and analysis by AI to identify morphotypic changes in disease. VisionSort for Disease Profiling Morphological changes in cells are hallmarks of many disease processes, from cancer to immune-related disorders. VisionSort’s high-resolution single cell profiling and AI-based population analysis can detect subtle morphological differences in diseased cells and uncover novel disease-related sub-populations that no other approach can. Disease Profiling Resources SEE ALL Phenotypic Diversity Profiling & isolation of disease-relevant phenotypes Unbiased Analysis Evaluate disease holistically, without the bias of labels or markers Novel Biological Insight Directly link genotypes to phenotypes to gain deeper disease insight High Throughput Analyze cells and sort at 3,000 eps
Drug Discovery
Phenotypic screening unleashed by morphology Pooled High-Content Screening of Genes and Drugs Add a new dimension to your phenotypic screens with the exhaustive capacity of morphological profiling. Compatible with both small molecule screens and CRISPR-based approaches, VisionSort opens the door to a wider range of phenotypes to screen. Discover new drugs and drug targets quickly and more efficiently with VisionSort. https://thinkcyte.com/wp-content/uploads/2023/11/vid-tcy-drug-discovery.mp4 Drug Discovery Resources SEE ALL VisionSort for Drug Discovery Identification of disease relevant phenotypes in phenotypic drug screening is critical. With VisionSort, unlock to potential to screen for a wider range of phenotypes from global cell states like metabolic activity and differentiation state to molecular transitions including changes in […]
Cell Therapy
Label-free, high throughput cell characterization and isolation based on high-resolution morphology and artificial intelligence. Label-free Monitoring and Isolation of Target Cells Ditch the labels. Optimize cell therapy R&D with high-resolution morphological profiling and AI. Expand the potential of your cell therapy R&D workflows with label-free cell sorting. Isolate immune cells of interest, select therapeutically meaningful cells, or monitor quality attributes for manufacturing QC…all without using external labels or markers. https://thinkcyte.com/wp-content/uploads/2023/11/vid-tcy-cell-therapy.mp4 Cell Therapy Resources SEE ALL VisionSort for Cell Therapy R&D Label-free process Characterize & sort cells without molecular labels, ideal for automated cell therapy R&D Closed System Cell characterization & isolation are performed within a closed, sterile system High Throughput […]
Applications
Company
ThinkCyte announces Premier Early Access Program for its new label-free cell characterization and sorting system
ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced today the launch of their Premier Early Access Program and recruitment of participation from key biopharmaceutical industry partners and leading academic centers. The program will give a select group of innovation-minded life science organizations from across the globe advanced access to ThinkCyte’s new label-free platform for cell analysis and sorting. Through a combination of proprietary optical signals and artificial intelligence, the system provides researchers with an entirely new data readout of ‘single-cell fingerprints’ and enables the isolation of target cells, untouched by external labels, for downstream research and development. “We have seen tremendous excitement and interest in […]
ThinkCyte shares applications of Ghost Cytometry with industrial and academic thought leaders
ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced today that applications of its Ghost Cytometry technology were presented at several leading industry meetings. In May, the company was selected to present applications of the platform to experts in drug discovery at the prestigious Keystone Symposia. The company was also selected to deliver a podium presentation at the 2022 International Association for the Advancement of Cytometry’s (CYTO) annual meeting, sharing applications in clinical medicine and cellular therapy with a talk entitled ‘Machine vision-based label-free cell analysis and sorting for clinical diagnosis and cell therapy.’ The company and its Ghost Cytometry platform were also selected as one […]
ThinkCyte’s novel label-free in-silico ghost cytometry published in eLife
ThinkCyte Inc., a company focusing on the development of novel cell analytics and sorting platforms for applications in cell therapy, drug discovery, and clinical diagnostics, announced today the publication of their “in-silico ghost cytometry (iSGC)” technology in eLife. The study was led by Dr. Sadao Ota, associate professor at Research Center for Advanced Science and Technology at the University of Tokyo, and ThinkCyte’s co-founder and CSO. The same team previously reported on the novel ghost cytometry (GC) technique, which utilizes proprietary optical designs combined with artificial intelligence to enable high-throughput, high-content analysis and sorting of cells, in a recent article in Science. Compared to conventional flow cytometry and microscopy techniques, […]
ThinkCyte Secures $26 Million in Series B Financing
Funding will be used to advance the development of AI-based cell analysis and sorting platforms in cell therapy and diagnostics ThinkCyte, Inc., a company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, announced today the completion of a $26 million (JPY 2.85 billion) Series B financing, led by SPARX Group with participation from Sysmex Corporation and Sumitomo Mitsui Trust Investment as well as existing investors, SBI Group and Itochu Technology Ventures. The company has raised a total of $45 million (JPY 4.9 billion) to date. “We are excited to welcome new investors, Sysmex and Sumitomo Mitsui Trust Investment, and to have continued support from existing […]
Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance
Commencing development of novel AI-based cell analyzers and testing techniques Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and ThinkCyte, Inc. (HQ: Bunkyo-ku, Tokyo, Japan; CEO: Waichiro Katsuda) announced today the signing of joint development and investment agreements during May 2021 for the commercialization of an AI-based cell analysis technology. As healthcare becomes more precise and personalized at an accelerated rate – in tandem with the advancement of technology, development of novel testing and diagnostic technologies with high clinical value is being sought to increase the accuracy of diagnoses and optimize treatment. Meanwhile, digitalization is rapidly gaining pace in healthcare fields such as telehealth, AI-powered medical imaging analysis, […]
ThinkCyte Awarded NEDO PCA Grant to Advance Label-free Cell Sorting Technology for Cell Therapy
ThinkCyte, a company focusing on the development of novel cell therapy, drug screening, and clinical diagnostic platforms, has been awarded a Product Commercialization Alliance (PCA) grant from the New Energy and Industrial Technology Development Organization (NEDO) of Japan. The grant will provide up to JPY250 million (approx. US$2.4 million) to advance research and development work on the company’s high-content label-free cell sorting system for cell therapy. To learn more about the grant program by NEDO, please visit NEDO’s website at https://www.nedo.go.jp/english/index.html.
ThinkCyte and National Cancer Center Japan Jointly Awarded AMED Grant for Isolation of Circulating Tumor Cells
ThinkCyte, a company focusing on the development of novel cell therapy, drug screening, and clinical diagnostic platforms, and National Cancer Center Japan (NCCJ) have been jointly awarded a Development of Advanced Measurement and Analysis Systems grant from the Japan Agency for Medical Research and Development (AMED) for the research and development of a high-accuracy method to isolate circulating tumor cells (CTCs) using Ghost Cytometry™ for genetic cancer profiling. Shinji Kosaka, M.D., Ph.D., Unit Leader of NCCJ, will lead the project in collaboration with Yoko Kawamura, Ph.D., Head of Applied Microfluidics of ThinkCyte. A liquid biopsy is a test conducted using a sample of body fluids, primarily blood, to detect cells […]
Hitachi and ThinkCyte Announce Collaboration to Develop an AI-driven Cell Analysis and Sorting System
Hitachi, Ltd (TSE: 6501, “Hitachi”) and ThinkCyte, Inc. (“ThinkCyte”) today announced that they have entered into a collaboration focused on developing an artificial intelligence (AI)-driven cell analysis and sorting system. Hitachi provides a broad range of solutions such as automated cell culture technologies to pharmaceutical companies in the value chain*1 of the regenerative medicine and cell therapy industry. Through the addition of this cell analysis and sorting system to the value chain, Hitachi continues contributing to cost reductions in the manufacturing of regenerative medicine and cell therapy products. Further, Hitachi and ThinkCyte are promoting collaboration with pharmaceutical companies and research institutes working in the field of regenerative medicine and cell […]
ThinkCyte Completes $15 Million Series A Financing
Financing accelerates the development of cell therapy and drug discovery platforms based on its proprietary image-based cell sorting system ThinkCyte, Inc., a company focusing on the development of novel cell therapy and drug screening platforms, today announced the completion of a US$15.3 million (JPY 1.65 billion) Series A financing, led by SPARX Group with participation from SBI Group, Itochu Technology Ventures, Inc. (ITV), and Fuyo General Lease. Existing investors Real Tech Fund and Osaka University Venture Capital also participated. This brings the total amount raised so far to US$18.5 million (JPY 2 billion.) “We are deeply grateful for the excitement and support our investors have expressed for our vision, technology, […]
ThinkCyte Selected for J-Startup Program
ThinkCyte was selected for J-Startup, a government-led initiative for supporting startups. “J-Startup” is a selective startup support program managed by the Ministry of Economy, Trade and Industry, Japan, and aims to cultivate promising startups to succeed in the world market and create new values with cutting-edge technology and business models. The selected companies are allowed to use various beneficial supports from the government and the private sectors, including an invitation to visit / exhibition tours to international events, business matching opportunities with major companies, financial support, and preferential application of the regulatory sandbox. With support from the J-Startup community, consisting of leading venture capitalists, business professionals, large corporations, and government […]
ThinkCyte Graduated Berkeley SkyDeck Cohort Program
In June, ThinkCyte joined the largest startup class to enter the Berkeley SkyDeck Cohort Program. Today, the company has graduated the program with six-months of formal training designed to help launch and grow ThinkCyte’s Ghost Cytometry technology, which is the world’s first high-throughput label-free, image-based cell sorting system that allows physical sorting based on high-content cell morphology. Founded in 2012, Berkeley SkyDeck is a joint program of the UC Berkeley Haas School of Business, the College of Engineering, and the Office of the Vice Chancellor for Research. The program combines hands-on mentorship of traditional accelerators with the vast resources and networks of a research university. The cohort is highly selective […]
ThinkCyte Selected for the Inaugural Class of Google Launchpad Accelerator Tokyo
After rigorous screening, ThinkCyte and six other startup companies were selected to participate in an international mentor program hosted by Google. The program, called Google Launchpad Accelerator Tokyo, is an equity-free, three-month program with three boot camps in Tel Aviv, Silicon Valley, and Tokyo. Each boot camp brings together 20 mentors who advise on various parts of starting and leading a business, including goal management and product market fit. The goal is to help startup companies overcome business, technology, and organizational scaling challenges. For more on the program, see this website on Google Launchpad Accelerator.
ThinkCyte Publishes Paper on “Ghost Cytometry” Method in Science
In response to the growing demand for advanced single-cell identification and sorting system, ThinkCyte, Inc. has developed Ghost Cytometry™. The system combines a novel imaging technique with machine learning to identify and sort cells with unprecedented high-throughput speed. Until now, conventional methods to sort cells have been based on total fluorescence intensity. But with Ghost Cytometry single-cells are sorted based on images which means richer information content and more discerning algorithms. As Dr. Yoko Kawamura, ThinkCyte’s scientist says succinctly “A picture is worth a thousand numbers”. This week ThinkCyte announces a high-profile publication in Science validating the use of ThinkCyte’s novel Ghost Cytometry method to image and sorting cells in […]
ThinkCyte Completes Seed Financing
ThinkCyte, Inc., a company focusing on developing a high-throughput imaging-activated cell sorting system, today announced the completion of a US$3.2 million (JPY 350 million) seed-financing round. ThinkCyte’s novel Ghost Cytometry™ method uses a proprietary combination of ghost motion imaging, microfluidics, and machine-learning to image and sort single-cells. It is of use in a variety of medical, research, and therapeutic applications, such as identifying and extracting circulating tumor cells in peripheral blood. To date, the ThinkCyte has raised more than $5 million (JPY 550 million) including angel investments and grants. This round of financing includednew investors, Real Tech Fund, Japan Science & Technology Agency (JST) and Osaka University Venture Capital. This […]
Thank you for your interest
[mwform_formkey key=”5″] Thank you for your interest. We will get back to you shortly. BACK TO INDEX
